This is supported by the aforementioned DAISY trial, in which 35% of cases maintained HER2 expression even after T-DXd resistance [33], and another study reviewed tumor tissues of paired pre- and post-T-DXd treatment showed that HER2 status remained unchanged or was increased in 38% of patients [33]. Here, ERBB2 is linked to neoplasm.